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ABSTRACT

Toxicity and Mitochondrial Delivery of Flavonol-Based Carbon
Monoxide-Releasing Molecules
by

Hector Jose Esquer Heredia, Master of Science
Utah State University, 2017

Major Professor: Dr. Abby D. Benninghoff
Department: Animal, Dairy and Veterinary Sciences

Carbon monoxide (CO) has been recently recognized as a gasotransmitter with
anti-inflammatory, vasoprotective, and anti-cancer properties, but the exact biological
targets of CO are still unknown. Our research group previously synthesized a class of
novel and structurally modifiable flavonol-based CO-releasing molecules (CORMs). The
base structure, Flav-1, is fluorescent, exhibits low cytotoxicity, and releases CO after
exposure to visible light. Heme-containing proteins in mitochondria are believed to be
important targets of CO. Previous reports indicate that addition of a triphenylphosphonium (TPP) tail allows chemical structures to target mitochondria. We
hypothesized that addition of a TPP tail of two or eight carbons in length to Flav-1 (MitoFlav-C2 or -C8) would facilitate targeting of mitochondria, and thus, localized lightinduced CO release. Cytotoxicity of these TPP-appended molecules was evaluated in
human umbilical vein endothelial cells (HUVEC) and lung epithelial carcinoma cells
(A549) using standard cell viability assays. Evaluation of cytotoxicity using the MTT
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assay revealed lower toxicity of Flav-1 in HUVECs when compared to A549 cells, but
addition of the TPP tails increased apparent cytotoxicity. However, unlike the MTT
assay, Flav-1 with and without tails had similar toxicity when measured in HUVECs by
the lactate dehydrogenase assay. Photo-degradation experiments were performed by
exposing cells to a 405 nm and/or 488 nm laser, or a bright-field source, until the
fluorescence emission was undetectable. Confocal microscopy images of HUVEC and
A549 cells treated with 100 µM of Mito-Flav-C2 or -C8 revealed an increase in cellular
uptake, compared to Flav-1. Localization of flavonols in proximity to mitochondria of
both cell lines was assessed using a confocal microscope by co-staining with Hoechst
33342 and MitoTracker Red CMXRos to visualize the nucleus and mitochondria,
respectively. When A549 cells were exposed to laser light or a bright-field source, the
fluorescence of Mito-Flav-C2 was lost, which indicates CO release. This work highlights
the successful synthesis of the first mitochondria-targeting CORMs that enable controlled
and localized release of CO to further study its physiological targets.
(97 pages)
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PUBLIC ABSTRACT
Toxicity and Mitochondrial Delivery of Flavonol-Based
Carbon Monoxide-Releasing Molecules
Hector Jose Esquer Heredia
Despite the reputation of carbon monoxide (CO) as a silent killer, new evidence suggests
that this gaseous molecule has anti-inflammatory, anti-cancer and vasoprotective properties.
Unfortunately, little is known about the role of CO in the body. However, proteins present in
mitochondria are believed to be important targets. We previously synthesized a class of novel
and structurally modifiable flavonol-based CO-releasing molecules (CORMs). Flavonols are
commonly found in fruits and vegetables. The base structure, Flav-1, is fluorescent, exhibits low
toxicity, and releases CO after exposure to visible light. Previous reports indicate that addition of
a triphenylphosphonium (TPP) tail allows chemical structures to enter mitochondria. We
hypothesized that addition of a TPP tail of two or eight carbons in length to Flav-1 (Mito-Flav-C2
or -C8) would facilitate targeting of mitochondria, and thus, localized light-induced CO release.
Toxicity of these TPP-tailed molecules was determined in human umbilical vein endothelial cells
(HUVECs) and lung epithelial carcinoma cells (A549), using standard cell viability assays.
Evaluation of toxicity using the MTT assay revealed lower toxicity of Flav-1 in HUVECs
compared to A549 cells, but addition of the TPP tails increased toxicity in both cell lines.
However, unlike the MTT assay, Flav-1 with and without tails had similar toxicity when
measured in HUVECs by the lactate dehydrogenase assay. Photo-degradation experiments were
performed by exposing cells until their light emission was undetectable by using lasers in the
near-UV and within the visible light spectrum. Localization of the compounds was observed
using a confocal microscope by co-staining with MitoTracker Red (MTR) and Hoechst to
visualize the mitochondria and nucleus, respectively. Fluorescence microscopy images of cells
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treated with Mito-Flav-C2 or -C8 revealed an increase in uptake, compared to Flav-1, plus colocalization with MTR, which suggests mitochondrial localization. A549 cells exposed to laser
light or a full spectrum of light lost all fluorescence of Mito-Flav-C2, which indicates CO release.
This work highlights the successful synthesis of the first mitochondria targeting CORMs, and that
CO release is achievable using different light sources. Moreover, these TPP-tailed CORMs will
allow for controlled and localized release of CO to further study its physiological targets.
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INTRODUCTION
Carbon monoxide (CO) may have the potential to become a future therapeutic,
despite its reputation as a killer gas. CO is a colorless, tasteless, odorless, and toxic
gaseous molecule. Briefly, CO is toxic due to its high binding affinity to hemecontaining proteins such as hemoglobin. CO binding to hemoglobin disrupts the oxygen
carrying capacity of this important transport protein and renders it unable to deliver
oxygen to tissues within the body. Therefore, high concentrations (5,000 ppm for 5 min)
or prolonged exposure to CO (1,500 ppm for more than 1 h) can lead to systemic
hypoxia, unconsciousness, and even death according to the National Institute for
Occupational Safety and Health (NIOSH) (1994).
In the late 1940s, Sjöstrand et al. (1949) observed that physiological
decomposition of hemoglobin in vivo produced CO. Later, Tenhunen and colleagues
(1968) determined that heme oxygenase (HO) enzymes were responsible for the
degradation of heme groups to produce CO, free iron, and biliverdin. These discoveries
led researchers to suspect possible physiological roles for endogenous CO. Several
groups have already elucidated the anti-inflammatory, (Chapman et al., 2001; Motterlini,
2007; Mu et al., 2014; Otterbein et al., 2000; Takagi et al., 2011) vaso-protective, (Kim
et al., 2015; Motterlini, 2007; Ndisang et al., 2004; Yang et al., 2014) and antiapoptotic properties (Al-Owais et al., 2015; Brouard et al., 2000) of CO. Additionally,
researchers have uncovered the capacity of CO to induce mitochondrial biogenesis,
which may modulate cellular metabolism (Almeida et al., 2015; Suliman and Piantadosi,
2014; Wang et al., 2016). Notably, these beneficial effects are observed at low
concentrations of CO. Therapeutic concentrations of CO gas range from 50 to 1000 ppm
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for up to 1 h in rats or mice, with 250 ppm being the most frequently used concentration
of CO (Motterlini and Otterbein, 2010). Although these concentrations of inhaled CO are
known to elicit beneficial effects, the exact concentration that accumulates inside the cell
is still unknown (Motterlini and Foresti, 2017). The lack of knowledge of exact
intracellular concentrations of CO also holds true for other delivery methods, as
discussed below.
Given such important physiological effects, studies involving the relationship
between HO and its enzymatic byproduct CO have inspired the development of
technologies that take advantage of these intricate pathways. Early experiments assessed
the effects of CO via inhalation or by overexpression or induction of HO-1 (Brouard, et
al., 2000; Otterbein, et al., 2000; Sato et al., 2001), which is the inducible isoform of
three distinct HOs. Although administration of exogenous CO through inhalation has
remained a viable option for research due to its relative simplicity, several drawbacks can
be noted. Example disadvantages include the poor reliability of using
carboxyhemoglobin (COHb) as a marker of exposure to CO and whether exposure to CO
at low concentration dosage intervals is more effective than a high single dosing
(Motterlini and Otterbein, 2010). Moreover, it remains unclear if a localized tissue
exposure to CO would increase efficacy of delivery to cellular targets since distribution
of the gaseous molecule after inhalation is dependent on the partition ratio between the
different tissues and body fluids (Schatzschneider, 2015). In addition, CO administered
by inhalation may require hospital visits and proper equipment handling by trained
personnel, which can prove difficult for continuous treatments. Despite these
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Figure 1. Chemical structures of first-generation CO-releasing molecules.
disadvantages, a promising CO delivery system has been developed. Covox DS is a
device developed by Ikaria that delivers CO gas in proportion to the patient’s body
weight and is independent of the patient’s respiration rate (Motterlini and Otterbein,
2010). Briefly, the device is adjusted to deliver CO gas at a mg per hour rate and releases
CO at the beginning of each inspiration.
For the reasons outlined above, the study of the therapeutic effects of CO may
require a safer and, perhaps, a more conventional drug-like approach. Thus, COreleasing molecules (CORMs) were developed to help localize the interaction of CO with
physiological targets and to decrease the amount of non-specific binding to hemoglobin
and myoglobin that occurs from inhaled CO (Motterlini and Foresti, 2017). Therefore,
CORMs may reduce the concentrations of CO required to produce the same physiological
effects as inhaled CO. Most CORM structures, including early iterations, are based on
metal-carbonyl complexes, which release CO upon ligand exchange (Figure 1; Table 1).
The first CORM, named CORM-1, contains manganese, requires UV-light to release CO,
and is insoluble in water (Mann, 2012). The second and third CORMs, CORM-2 and
CORM-3, replaced manganese with ruthenium and are soluble in DMSO and water,
respectively. These two important CORMs have been extensively utilized with more
than 200 published papers describing their use, to date (reviewed in Mann, 2012).

b

(Motterlini, 2007)
(Vummaleti et al., 2012)
c
(Marques et al., 2012)
d
(Ji et al., 2017)
e
(Romanski et al., 2013)
f
(Peng et al., 2013)
h
(Palao et al., 2016)
g
(Antony et al., 2013)
i
(Anderson, et al., 2015)

a

CORM-1a
CORM-2a
CORM-3a
CORM-A1a
CORM-401b
ALF785c
BW-CO-101d
rac-1e
rac-8e
BW-ETCO-101d
Diketone derivativef
Xanthene-9-carboxylic acidg
BODIPY derivativeh
Flav-1i

Name
UV-light
Interaction with heme-proteins
Solution chemistry
Solution chemistry
Solution chemistry
Solution chemistry
Solution chemistry
Esterases
Esterases
Esterases
Visible light
Visible light
Visible light
Visible light

CO-release trigger
Fe
Ru
Ru
B
Mn
Mo
None
Fe
Fe
None
None
None
None
None

Metal
Center
PhotoCORM
Ligand exchange
Ligand exchange
Ligand exchange
Ligand exchange
Ligand exchange
Ligand exchange
Enzyme triggered-CORM
Enzyme triggered-CORM
Enzyme triggered-CORM
PhotoCORM
PhotoCORM
PhotoCORM
PhotoCORM

Classification

Table 1. Summary of the Properties of Example CO-Releasing Molecules (CORMs)

No
No
No
No
No
No
Product only
No
No
No
Yes
Yes
Yes
Yes

Fluorescence
emission

Organic solvents
Organic solvents
Aqueous solutions
Aqueous solutions
Organic solvents
Aqueous solutions
Organic solvents
Aqueous solutions
Aqueous solutions
Organic solvents
Micelles
Aqueous solutions
Aqueous solution
Organic solvents

Solubility
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5
Furthermore, experiments using these compounds were able to mimic the effects of CO
inhalation and upregulation of HO-1 expression (Otterbein et al., 2016), making them
attractive alternatives for CO delivery. However, CORM-3 releases CO in solution very
rapidly (t½<1 min). A very short half-life, the presence of several isomeric forms, and a
variable rate of CO release limit the applications of CORM-3 (Johnson et al., 2007;
Mann, 2012; Motterlini and Otterbein, 2010).
Therefore, to explore other desirable features, available CORMs were modified or
new CORMs were synthesized. These modified or new molecules replaced ruthenium
with different metals, such as iron, cobalt, iridium, rhenium, tungsten, molybdenum, and
chromium. New and modified CORMs enabled tuning of the rate of CO release and
increased cellular uptake of the compounds (Kautz et al., 2016; Schatzschneider, 2015).
Figure 2 shows the chemical structure of several later generations of ligand exchange
CORMs. CORM-401 is able to release three CO molecules per mole of compound at pH
7.4 and 37 °C. Interestingly, the reaction appears to be reversible by recapturing released
CO. However, in the presence of a CO target, such as myoglobin, the reversible reaction
is prevented, which may suggest some targeting capacity (Crook et al., 2011). A notable
non-metal example is CORM-A1, which contains boron. At physiological conditions,
CORM-A1 has a 21 min half-life for CO release (Figure 2). Dr. Wang and colleagues
(2014) developed a click chemistry approach to synthesize metal-free CO-releasing pro
drugs. Expanding on their previous work, Wang and group were able to improve the
previous click chemistry design to a more structurally modifiable intramolecular COreleasing pro drug, BW-CO-101 (Ji et al., 2016). On the other hand, Marques et al.
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Figure 2. Chemical structures of example CORMs that operate via a ligand-exchange
mechanism.

(2012) developed molybdenum-containing CORMs, such as ALF794 (Figure 2), aimed to
deliver CO in a targeted manner to the liver. ALF794 efficiently elevated CO
concentrations in the liver, whereas removal of the methyl substituents on this structure
(illustrated by molecule ALF795) enhanced protection of the liver in vivo in the
acetaminophen-induced liver injury mouse model.
When designing experiments, investigators must consider that the metalcontaining fragments remaining after CO release may produce unknown biological
interactions (Schatzschneider, 2015). The presence of free metals could catalyze Fenton
reactions (Mann, 2012), which are a source of reactive oxygen species (ROS). Ideally,
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Figure 3. Chemical structures of CORMs that operate via an enzyme-triggered
mechanism.
CORMs will be administered as oral drugs that can release CO systemically at
established rates or be targeted to specific locations in cells or in the body. In addition,
CORMs may benefit substantially by controllable CO release trigger mechanisms, such
as enzymatic catalysis (ET-CORMs), photolysis (photoCORMs), and even magnetic
heating (Kautz, et al., 2016).
The ability to trigger CO release from ET- or photoCORMs allows for precise
spatial and/or temporal control of the release of CO. However, concentrations of
intracellular CO release may be limited by the presence of extracellular esterases in vivo
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(Jobsis et al., 2007). Romanski et al. (2013) measured in vitro the protective effects of
rac-1, an ET-CORM, and its derivatives (Figure 3) on hypothermia-associated cell
damage, and noted that structural modifications modulated the CO-associated protective
effect. The compounds were modified by shifting the double bonds present in the ring
structure into an inner or outer position with respect to the ester, along with various
substituent combinations. The variability of biological activity of these compounds
among cell lines can be detrimental to their development as a therapeutic agent.
However, these differences can be beneficial if ET-CORMs are developed to target
specific cell lines and to produce specific biological activities and not others. Adding to
the ET-CORM field, Ji et al. (2017) modified their click chemistry CO-releasing pro
drugs to include esterase-catalyzed CO release, as illustrated by the molecule BW-ETCO101 (Figure 3). Importantly, ET-CORMs may be modified to include other enzymatic
systems, such as proteases or decarboxylases, or a higher affinity to specific esterases
present in target cells.
The first CORM structure developed, CORM-1, is a photoCORM that requires
exposure to UV-light for CO release (Mann, 2012). Like ET-CORMs, photoCORMs
provide an attractive mechanism for CO release. Whereas ET-CORMs only allow for
spatial control, photoCORMs provide for both spatial and temporal control. At the time
this work was initiated, most photoCORM structures required near UV-light to undergo
CO release, making them difficult to be used as future therapeutics because of the
potential for UV-induced cell damage. The use of lower energy wavelengths for
photolysis is an important aspect of photoCORM development because it reduces the
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HO
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N
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Figure 4. Chemical structures of CORMs that operate via a light-induced mechanism.

damage caused by UV-light to cells, while also allowing for deeper penetration of light
into tissue. Importantly, Chakraborty et al. (2014a; 2014b) showed that different
ligand/coligand combinations on metal-coordinated systems can lower the energy of light
required for and the rate of CO release. Notably, only a few metal-free photoCORMs
have been synthesized, including 1) a xanthene-9-carboxylic acid, which releases CO
when exposed to 500 nm light at a pH range of 5.7-7.4 in aqueous solution (Antony, et
al., 2013); 2) a micelle-encapsulated diketone derivative (Figure 4), which releases two
equivalents of CO when irradiated at 470 nm (Peng, et al., 2013); 3) borondipyrromethene (BODIPY) derivatives (Figure 4) capable of releasing CO when exposed
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O

hν
O2

O

OH

O
OH

CO

O

O

Flav-1
Irr-Flav-1
Figure 5. Reactivity of Flav-1 in the presence of 419 nm light (in DMSO) and O2. This
reaction generates free CO and the light irradiated product of Flav-1 (Irr-Flav-1).
(Anderson et al., 2015)

to visible and near infrared light (300-730 nm) (Palao, et al., 2016); and 4) a structurallytunable flavonol derivative (Flav-1) that releases CO (Figure 5) when exposed to 419 nm
light and in the presence of oxygen (Anderson, et al., 2015).
The work presented in this thesis was performed on flavonol-based photoCORMs
developed by Dr. Berreau and colleagues (Anderson, et al., 2015). Flavonoid compounds
are commonly found in fruits, vegetables, and seeds and are known to have anti-oxidant
and free-radical scavenging activities (Chahar et al., 2011). The core structure of Flav-1
represents a new class of metal-free photoCORMs. Notably, Flav-1 has several
important features that are relevant in the field of CORMs. First, Flav-1 is excitable with
blue light (BP 470/40 filter) in cell culture media and has detectable emission using a
standard green fluorescent protein filter (BP 525/50 filter) (Figures 6 and 7). Second,
Flav-1 is stable and soluble in media supplemented with 10% fetal bovine serum (FBS) at
37 °C and pH of 7.4. Third, the photoreaction releases one CO equivalent and results in
the loss of the fluorescence emission characteristic of Flav-1. The photodegradation of
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Figure 6. Absorption spectrum of Flav-1. Flav-1 was solubilized in DMEM-F12 media
supplemented with 10% FBS 100 µM. Data shown with permission of collaborators
Tatiana Soboleva and Lisa Berreau, Utah State University.
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Figure 7. Emission spectra of Flav-1. Flav-1 was solubilized in DMEM-F12 media
supplemented with 10% FBS to a concentration of 100 M and exposed to 410 nm (solid
line) or 480 nm (dashed line) excitation light. Data shown with permission of
collaborators Tatiana Soboleva and Lisa Berreau, Utah State University.
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Flav-1 yields a single, characterized, non-toxic product, Irr-Flav-1 (Figure 5). Recently,
Popova and colleagues (2017) determined that Flav-1 is stabilized in part to its anionic
form when solubilized in 1:1 DMSO:PBS at pH 7.4. This stabilization of the anionic
form red-shifts the absorption maximum of Flav-1 and its emission wavelengths
compared to being solubilized in acetonitrile. Furthermore, Figure 6 shows evidence of
the presence of the anionic form of Flav-1 in media supplemented with FBS, as indicated
by the observed spectral band at approximately 480 nm. Thus, the anionic form of Flav-1
in media allows for CO release at higher wavelengths of light compared to other
solutions.
The structural tunability of Flav-1 has allowed us to explore modifications that
could increase cellular uptake or target the molecule to specific organelles. Due to the
important roles of mitochondria in cellular metabolism and cell survival, a number of
molecules have been targeted to these important organelles. A successful approach to
localize molecules to the mitochondria has been the use of a triphenylphosphonium (TPP)
cation moiety (Figure 8). This structural motif allows molecules to cross lipid bilayers
and to accumulate in the mitochondria driven by a large electric potential (Zielonka et al.,
2017). For example, by attaching a TPP cation moiety to the active phenolic group of
vitamin E (MitoE2), Smith, et al. (1999) showed that the modified antioxidant was able
to protect the mitochondria from oxidative damage by decreasing both lipid peroxidation
and protein damage (Figure 8). Also, several other antioxidant compounds have been
used as possible mitochondria-targeting therapeutics, such as MitoSOD, MitoPeroxidase,
MitoQ10, and MitoTEMPOL (Figure 8) (Murphy and Smith, 2007). MitoQ10 has been
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Figure 8. Chemical structures of the TPP motif and several available TPP-appended
compounds.

shown to protect against the development of hypertension, improve endothelial function,
and reduce cardiac hypertrophy (Graham et al., 2009).
As previously stated, mitochondria maintain proper metabolic control in cells.
These organelles are not only the major site of ATP production, but they coordinate other
critical metabolic pathways through the Krebs cycle, fatty acid metabolism, cell
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proliferation, inflammatory and anti-inflammatory pathways, and cell viability (Suliman
and Piantadosi, 2014). Although experiments have elucidated the beneficial effects of
low amounts of CO in vivo, a mechanistic understanding is lacking. Mitochondria have
been proposed to be the target organelle for CO-induced biological effects. For example,
cytochrome c oxidase (COX), also known as Complex IV, is a known binding target for
CO. However, various studies have yielded contrasting results with respect to COXspecific activity (Almeida et al., 2012; Queiroga et al., 2011; Zuckerbraun et al., 2007).
For example, Almeida and colleagues (2012) observed an induction of COX activity in
isolated mitochondria of primary astrocytes when treated with 10 µM of CO.
Meanwhile, Queiroga et al. (2011) observed a transient effect on COX activity of liver
mitochondria treated with 10 µM CO. Briefly, after 10 min, COX activity was
prevented, while 30 minutes after exposure COX activity was slightly increased. Finally,
Zuckerbraun and colleagues (2007) observed a decrease in COX activity after exposure
to 250 ppm (8.9 mM) of CO in permeabilized RAW 264.7 cells. These differences might
be explained by the different concentrations tested, periods of exposure, and time points
in which COX activity was measured (Queiroga et al., 2012), and in Zuckerbraun’s
experiment, the use of whole cells as opposed to isolated mitochondria. Interestingly, the
rate of mitochondrial respiration appears to be modulated when treated with CORM-3,
and it can be increased or decreased depending on the treatment concentration, ranging
from 0.5-50 µM (0.14-1.4 ppm) (Lancel et al., 2009). Although the experiments
performed by these scientists showed important biological effects attributed to CO, it
remains a challenge to compare their results in a systematic manner. Thus, a current
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limitation in the field of CO is the development of a unifying delivery method that can
localize in the biological compartments of interest.
In addition to COX activity, mitochondrial biogenesis, an increase in number of
mitochondria, seems to play a major role in the biological effects produced by CO.
Therefore, COX activity, mitochondrial respiration, and mitochondrial biogenesis appear
to be linked in the improvement of metabolism and energetic status on the mitochondria
(Almeida, et al., 2015; Lancel, et al., 2009; Queiroga, et al., 2012; Suliman et al., 2007;
Suliman and Piantadosi, 2014; Suliman and Piantadosi, 2016; Wang, et al., 2016). A
recent paper by Sun and colleagues (2017) showed that CO treatment attenuated
oxidative stress triggered by oxidized low density lipoproteins. Briefly, human umbilical
vein endothelial cells (HUVECs) were treated with 5-50 µM of CORM-2, and then cell
viability was assessed. They observed a decrease in cell death triggered by oxidative
stress when cells were treated with 20 and 50 µM of CORM-2. CORM-2 suppressed
cytochrome c release from the mitochondria, inhibited the mitochondrial permeability
transition pore, and inhibited the Wnt/β-catenin pathway. These apparent molecular
responses to CORM-2 are all known to modulate cell apoptosis.
Until recently, most CORMs released CO spontaneously upon solubilization,
which limited their ability to release CO within specific tissues or organs. Scientists
noted the limitations of this model and implemented different methods of CO-delivery.
In addition to the previously mentioned ET-CORMs and photoCORMs, other modified
CORMs have been designed. Kautz et al. (2016) described these modifications as
CORM conjugates, which involve the use of peptides, polymers, micelles, nanoparticles,
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dendrimers, biocompatible metal-organic frameworks, and self-assembled protein cages
to accumulate the compounds into different tissues. These conjugated CORM structures
aimed to reduce cytotoxicity of the parent compound, enhance permeability and
retention, and extend the half-life of the CO release reaction to facilitate intracellular CO
delivery. However, to our knowledge, none of these conjugates facilitated delivery of the
CORM to specific cellular organelles.
To fully understand the mechanistic effects of CO, the field would be advanced
by mitochondria-targeting CORMs that enabled more precise study of physiological
targets of this gaseous molecule. Therefore, our objective was to use the structurallytunable framework of Flav-1 (Anderson, et al., 2015) to design CORM structures that
target mitochondria, thus facilitating delivery of CO to this organelle in a manner under
both spatial and temporal control. We hypothesized that modification of the Flav-1
structure by addition of a TPP tail moiety of varying lengths (2 and 8 carbons) would
facilitate targeting of this CORM, and thus CO release, to the mitochondria. Additional
specific objectives were to assess the cytotoxicity of these modified compounds using
HUVEC and A549 cell models and confirm their mitochondrial targeting capability via
confocal microscopy.
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MATERIALS AND METHODS
Synthesis of targeting compounds. Synthesis of photoCORMs to target the
mitochondria was performed by members of the Berreau laboratory at Utah State
University. Mito-Flav-C2 (2 carbon tail length) was synthesized according to the scheme
depicted in Figure 9. A separate preparation of the TPP tail and flavonol was required
before their coupling. Hence, the TPP tail was synthesized in a one-step reaction
between 2-bromoethylamine hydrobromide and triphenylphosphine. Flav-1 (3-hydroxy2-phenyl-benzo[g]chromen-4-one) was synthesized as previously described (Anderson, et
al., 2015), but using a p-carboxy-benzaldehyde. The obtained tail and flavonol were
subsequently coupled to form Mito-Flav-C2 with a final yield of 68%. The purified
product was characterized by NMR spectroscopy and mass spectroscopy to confirm the
structure, and the experimental results were in good agreement with the theoretical values
(Figure A1). Absorption and emission spectra for Mito-Flav-C2 are also provided in the
appendix (Figures A2-A4).
Mito-Flav-C8 was synthesized as detailed in Figures 10-11. A separate
preparation of tail and flavonol was necessary before their coupling. Hence, the tail was
synthesized in a five-step reaction pathway (Figure 10). Initially, 1,8-octanediol was
brominated to yield 8-bromo-1-octanol, which was subsequently combined with
phthalimide to obtain 2-(8-hydroxyoctyl)-1H-isoindole-1,3(2H)-dione. The latter was
mixed with hydrazine monohydrate to give 8-amino-1-octanol that was further
brominated to give 8-amino-1-bromooctane hydrobromide salt. The obtained salt was
refluxed with triphenylphosphine to yield C8-TPP. The obtained tail and flavonol were
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Figure 9. Scheme depicting synthesis of Mito-Flav-C2 (two carbon length TPP-tail).
TPP, triphenylphosphine; C2-TPP, two-carbon length TPP-tail; ACN, acetonitrile; EDC,
1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide; HOBt, hydroxybenzotriazole; DMF,
dimethylformamide.

subsequently coupled to form Mito-Flav-C8 with a final yield of 62% (Figure 11). The
purified product was characterized by NMR spectroscopy and mass spectroscopy to
confirm the structure, and the experimental results were in good agreement with the
theoretical values (Figure A5). Emission and absorption spectra for Mito-Flav-C8 are
also provided in the appendix (Figures A6-A8).
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Figure 11. Scheme depicting synthesis of Mito-Flav-C8 using carboxy-Flav-1 and an
eight-carbon triphenylphosphine tail (C8-TPP). EDC, 1-Ethyl-3-(3dimethylaminopropyl) carbodiimide; HOBt, hydroxybenzotriazole; DMF,
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Absorption and emission spectra of flavonol-based compounds. To determine the
appropriate excitation wavelength for the flavonol-based compounds for confocal
experiments, absorption spectra of all compounds at 100 µM were measured using a
Varian Cary 50Bio spectrophotometer (Agilent Technologies, Santa Clara, CA) at 37
°C, in media prepared with 10% (v/v) FBS (Caisson Laboratories, Logan, UT) and
without FBS in a cell-free system. The absorbance profiles for these TPP-appended
photoCORMs were different in the presence of FBS, noted by the additional absorption
feature at 480 nm (Figures A4 and A8). The presence of this absorption feature allowed
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for the illumination of the photoCORMs well within the visible light range for
subsequent in vitro experiments described below. Light emission intensity was measured
using a Shimadzu RF-530XPC spectrometer in the range of 295-800 nm by exciting the
compounds at two different wavelengths, 410 and 480 nm, to reproduce as closely as
possible the lasers on the confocal microscope to be used (405 and 488 nm) (Figure 12).
During the preparation of stock solutions of Flav-1 and the TPP-appended compounds for
spectroscopic analyses, it was noted that the compounds tended to precipitate when
solubilized in aqueous solution or culture media without the presence of FBS. This
observation suggested that the photoCORMs may adhere or otherwise interact with
serum proteins in FBS, resulting in reduced free compounds in the media. Thus, when
considering the concentrations for in vitro experiments described below, the
concentration specified is the nominal concentration that does not account for potential
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Figure 12. Emission intensity spectra for Flav-1, Mito-Flav-C2, and Mito-Flav-C8.
Spectra were obtained for each CORM at 100 M in DMEM F12 media with 10% FBS
after excitation at 410 nm (A) or 480 nm (B). Approximate wavelengths for maximum
emission intensities are shown. Data shown with permission of collaborators Tatiana
Soboleva and Lisa Berreau, Utah State University.
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Figure 13. Photodegradation reaction of Mito-Flav-C2. Scheme depicts reaction to
generate irradiated (Irr)-Mito-Flav-C2 following exposure of Mito-Flav-C2 to light (380450 nm and 2450 lux of light power) for 24 h in the presence of oxygen. Red text
indicates proposed source of new oxygen atoms in the product based on prior analysis of
the reactivity of Flav-1.

binding of photoCORMs to serum proteins. The concentration of free photoCORMs
available for cellular uptake was likely to be substantially lower.
Generation of photodegraded products. Flav-1, Mito-Flav-C2, and Mito-Flav-C8
were subjected to light exposure for 24 h using a Rayonet (Branford, CT) photoreactor
equipped with eight RPR-4190A lamps. These lamps emitted light in a wavelength range
of 380-450 nm with an excitation maximum at 419 nm. The light intensity power of the
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Figure 14. Photodegradation reaction of Mito-Flav-C8. Scheme depicts reaction to
generate irradiated (Irr)-Mito-Flav-C8 following exposure of Mito-Flav-C8 to light
(380-450 nm and 2450 lux of light power) for 24 h in the presence of oxygen. Red text
indicates proposed source of new oxygen atoms in the product based on prior analysis of
the reactivity of Flav-1.

photoreactor was measured using an Apogee Instruments (Logan, UT) MQ-500 full
spectrum quantum meter and was determined to be 2450 lx (lumens per meter squared).
The photodegraded products of Flav-1, Mito-Flav-C2, and Mito-Flav-C8 (indicated by
irr- prefix) were used in experiments to compare the cytotoxicity of the parent compound
and the light-induced product. Completion of the photochemical reaction was confirmed
by 1H NMR (Figures A9-A10). Schemes outlining the proposed reactions of Mito-Flav-
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C2 and Mito-Flav-C8 to generate irradiated products following exposure to visible light
are provided in Figures 13-14.
Cell culture. Human umbilical vein endothelial cells (HUVECs) were selected
because they are a well-established primary cell line model suitable for in vitro oxidative
stress studies. HUVECs are known to experience oxidative stress and altered
mitochondrial respiration in disease states, such as vascular disease. CO is well known
for its vasoprotective and vasodilatory capacity, in addition to reducing oxidative stress
damage (Garcia-Gallego and Bernardes, 2014). HUVECs were obtained from ATCC
(Manassas, VA, Cat. No. CRL-1730). Cells were cultured in F-12K medium (Gibco,
Carlsbad, CA) supplemented with 0.03 mg/ml endothelial cell growth supplement
(Sigma-Aldrich, St. Louis, MO), 10% (v/v) FBS, 0.1 mg/ml heparin (Sigma-Aldrich),
and 100 U/ml streptomycin-penicillin solution (Gibco) in a humidified incubator at 37 °C
with 5% CO2. Complete media was replenished every three days, and cells were subcultured into T-75 flasks when they attained 90% confluence. At sub-culture, cells were
detached by adding 3 ml of Trypsin-EDTA 1X solution (Caisson Laboratories) for 3-5
min, then neutralized with 8 ml of fresh media. HUVECs were counted using a Cell
Countess instrument (Thermo Fisher Scientific, Boston, MA) according to the
manufacturer’s protocol. The minimum seeding density used to sub-culture into T-75
flasks was 4,000 cells/cm2. HUVECs at passages one through eight were used in all
experiments.
Human lung adenocarcinoma epithelial cells (A549) are a well-characterized
cancer cell line used in many cytotoxicity experiments for their rapid and robust in vitro
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growth. Also, this cell line has been used in prior studies with flavonol-based
compounds, such as quercetin (e.g., Andreescu et al., 2005; Zerin et al., 2013). A549
cells were obtained from ATCC (Cat. No. CCL-185). Cells were cultured in phenol redfree DMEM-F12 media (Caisson Laboratories) supplemented with 10% FBS in a
humidified incubator at 37 °C with 5% CO2. Complete media was replenished every
three days, and cells were sub-cultured into T-75 flasks when they attained 90%
confluence. At sub-culture, cells were detached by adding 3.5 ml of Trypsin-EDTA 1X
solution (Caisson Laboratories) for 5-10 min, then neutralized with 8 ml of fresh media.
The minimum seeding density used to sub-culture into T-75 was 2,000 cells/cm2. Cell
counts were performed in the same manner as HUVECs.
Cytotoxicity assays. Cell viability was assessed using the 3-(4,5-dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The MTT assay is a wellestablished cytotoxicity assay used to detect the reduction of MTT to formazan by
NADPH-dependent oxidoreductases, an indicator of cellular viability (Tolosa et al.,
2015). HUVEC or A549 cells were seeded in 96-well tissue culture plates at a density of
10,000 cells/well and in a volume of 190 µl/well and then allowed to attach for 24 h.
Cells were then treated in triplicate with Mito-Flav-C2, Mito-Flav-C8, Flav-1, or their
irradiated versions at concentrations ranging from 0.08 μM to 100 μM and incubated for
24 h. During and after the addition of light-sensitive chemicals, all plates were handled
in a dark room and performed in triplicates. Mito-Flav-C2, Mito-Flav-C8, and their
irradiated versions were solubilized in dimethylsulfoxide (DMSO) or ethanol and added
to cells at a final concentration of 0.4% and 0.2% (v/v), respectively. Flav-1 and Irr-
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Flav-1 were solubilized in DMSO and added to cells at a final concentration of 0.4%
(v/v).
MTT (Sigma-Aldrich) was prepared fresh at 5 mg/ml in sterile phosphatebuffered solution (PBS), and then passed through a 0.22 µm polyethersulfone filter.
Cells were then treated with 20 µl/well of MTT solution and placed in an incubator at 37
°C and 5% CO2 for 4 h. Then, cell culture media was removed, and 200 µl/well of
DMSO was added and mixed to solubilize the formazan pellets. Finally, the plates were
placed in a Turner Biosystems Modulus™ Microplate reader (Promega Corp., Madison,
WI) and absorbance was measured at 560 nm and 750 nm (background). Backgroundsubtracted absorbance values were normalized to the vehicle control (0.4% DMSO).
Cytotoxicity data were analyzed using GraphPad Prism version 7 (La Jolla,
California). The half-maximal inhibitory concentration (IC50) was defined as the
concentration at which the tested compound inhibited cell growth to 50% of the control.
These concentrations were calculated using a four-parameter nonlinear regression with
the bottom of the curve constrained to zero. For each chemical tested, a one-way
ANOVA with Tukey post hoc test was used to compare cytotoxicity values to the lowest
concentration tested to determine the lowest concentration of photoCORM that produced
a detectable reduction in cell viability.
The Pierce Lactate Dehydrogenase (LDH) Assay Kit (Thermo Fisher Scientific)
was used per the manufacturer’s recommended protocol. The LDH assay is also a widely
accepted and standard cell viability assay, which measures extracellular LDH released by
cells with a compromised plasma membrane (Korzeniewski and Callewaert, 1983).
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Briefly, HUVECs were optimized to a cell density of 8,000 cells/cm2 to account for
variability between cell lines in respect to LDH activity in the extracellular environment.
The 96-well plates were seeded in a volume of 190 µl/well and allowed to attach for 24 h.
Cells were then treated in triplicate with Mito-Flav-C2, Mito-Flav-C8 or Flav-1 and their
irradiated versions at concentrations ranging from 0.08 μM to 100 μM with a final
DMSO concentration of 0.4% (v/v) and then incubated for 24 h in the dark. The samples
were placed in the microplate reader, and absorbance was measured at 450 nm and 750
nm. Background-subtracted absorbance values were normalized to the vehicle control
(0.4% DMSO). Per the manufacturer’s protocol, percent cytotoxicity was calculated by
subtracting the LDH activity of the spontaneous LDH release control (vehicle-treated)
from the LDH activity of chemical-treated sample, dividing by the total LDH activity
[(maximum LDH release control activity) – (spontaneous LDH release control activity)],
and multiplying by 100. Analysis of LDH cytotoxicity data was performed as described
previously for MTT assays.
Confocal microscopy. HUVEC or A549 cells were sub-cultured at 100,000
cells/cm2 and incubated for 24 h to allow for proper adherence. Cells were then treated
with Mito-Flav-C2, Mito-Flav-C8, or Flav-1 and incubated for an additional 4 h.
Afterward, cells were washed thrice with fresh media, the appropriate co-stains were
added, and the cells were incubated for 15 min at 37 °C. Finally, the cells were washed
thrice with fresh media and then imaged using a Zeiss LSM 710 confocal microscope
(Thornwood, NY). The images were acquired using a 20x or 63x oil immersion objective
with the following excitation lasers and emission ranges: Hoechst 33342 Stain (405
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nm/410-492 nm); Mito-Flav-C2, Mito-Flav-C8 or Flav-1 (488 nm/495-581 nm); and
MitoTracker Red CMXRos (561 nm/579-600 nm). Gain and laser intensity were
adjusted to obtain the best signal-to-noise ratio. To enhance visualization, the reference
dye channels (Hoechst 33342 and MitoTracker Red CMXRos) were adjusted by using the
“best-fit” parameter available in the Zeiss Zen 2.3 Lite software (Thornwood, NY).
Preliminary confocal experiments with Mito-Flav-C8 solubilized in ethanol.
Several initial confocal experiments were performed using Mito-Flav-C8 solubilized in
ethanol at a final concentration of 0.2% (v/v) on cells grown in 4-well Millicell® E-Z
Slides obtained from Millipore (Billerica, MA). However, the fluorescence signal was
markedly lower compared to Mito-Flav-C8 solubilized in DMSO, and the stock solution
of Mito-Flav-C8 prepared in 100% ethanol would not consistently remain dissolved (data
not shown). Thus, all further microscopy experiments used CORMs solubilized in
DMSO.
Qualitative assessment of emission intensity of photoCORMs in vitro. HUVEC
and A549 cells were sub-cultured in 4-well Millicell® E-Z Slides and allowed to adhere
for 24 h. Each chamber had a final volume of 850 µl of media. Cells were treated with
25-100 µM of Mito-Flav-C2, Mito-Flav-C8, or Flav-1 prepared in DMSO (≤0.4% (v/v)
final concentration in media), and co-stained with 0.5% (v/v) Hoechst 33342
(ImmunoChemistry Technologies, LLC, Bloomington, MN). Both cell lines were
incubated, washed, and imaged as outlined above.
Photodegradation of Mito-Flav-C2. A549 cells were sub-cultured in 35 mm glass
bottom dishes obtained from MatTek (Ashland, MA) and allowed to adhere for 24 h for
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live cell imaging. Cells were treated with 25 µM Mito-Flav-C2 in DMSO (0.1% (v/v)
final concentration in media) and co-stained with 0.5% (v/v) Hoechst 33342. An initial
image was obtained prior to laser light exposure. Images were then acquired every 5 min
of continuous exposure to 405 and/or 488 nm lasers. A loss of fluorescence emission was
indicative of CO release. A549 cells were incubated, washed, and imaged as outlined
above.
Mitochondrial targeting of Mito-Flav-C2 and Mito-Flav-C8. HUVEC and A549
cells were sub-cultured in 4-well Millicell® E-Z Slides and allowed to adhere for 24 h.
Each chamber had a final volume of 850 µl of media. Cells were treated with 100 µM
Mito-Flav-C2, Mito-Flav-C8, or Flav-1 prepared in DMSO (0.4% (v/v) final
concentration in media), and co-stained with 0.5% (v/v) Hoechst 33342 and 300 nM
MitoTracker Red CMXRos (Thermo Fisher Scientific). Both cell lines were incubated,
washed, and imaged as outlined above. In addition, a set of higher magnification images
was acquired to enhance visualization of mitochondria morphology in A549 cells treated
with 75 µM of Mito-Flav-C2 (0.3% (v/v) final concentration in media). Software image
capture settings (Zeiss Zen 2.3 Lite) were adjusted to obtain higher magnification images,
including increased pixel dwell time (greater photon capture), increased total pixels
captured and increased zoom factor (set to 2x).
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RESULTS
Cytotoxicity determined by the MTT assay. Two cytotoxicity assays were
employed to compare the toxicity of the parent CORM structure, Flav-1, and the two TPP
tail-modified structures, Mito-Flav-C2 and Mito-Flav-C8, in both HUVEC and A549
cells. First, as reported previously (Anderson, et al., 2015), Flav-1 was observed to be
moderately toxic to A549 cells, with an average IC50 value of 80.2±3.3 µM (Table 2;
Figure 15A). The highest Flav-1 concentration of 100 µM reduced cell survival by 62%
after 24 h, whereas concentrations lower than 10 µM did not alter cell viability.
Irradiation of this CORM with visible light, which triggers release of CO, eliminated the
apparent moderate toxicity of Flav-1, as treatment of A549 cells with Irr-Flav-1 for 24 h
did not appreciably decrease the number of viable cells compared to vehicle control

Table 2. Calculated IC50 Values for Flav-1, Mito-Flav-C2 and Mito-Flav-C8 in A549
and HUVEC Cells as Determined by the MTT Assay.
Flav-1

A549
HUVEC
DMSO
EtOH

Mito-Flav-C2

Mito-Flav-C8

Parent

Irradiated

Parent

Irradiated

Parent

Irradiated

80.2±3.3

ND

14.1±2.7

ND

8.48±4.0

69.1±11

L

ND

1.51±1.4
L

L
L

8.40±3.6
31.9±14

90.0±7.5
108±14

IC50 values were calculated by non-linear regression analysis (four-parameter, variable
slope) was performed (GraphPad Prism v. 7, La Jolla, CA) to generate the
concentration-response curve for each chemical using each cell line. Values represent
the mean ± SEM (n = 3 independent experiments, except n = 6 for Flav-1 in A549
cells). ND, no significant decrease in cell viability; L, less than 50% decrease in cell
viability.
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Figure 15. Toxicity of Flav-1, Mito-Flav-C2, Mito-Flav-C8, and their irradiated products
in A549 cells measured by the MTT assay. Values shown are the mean ± SEM percent
viability of cells with respect to the control (0.4% DMSO) for various concentrations of
Flav-1 (A), Mito-Flav-C2 (B) and Mito-Flav-C8 (C). Cell viability data and non-linear
regression analyses (four-parameter, variable slope) are shown for the native compounds
(open symbols, dashed lines) and their photo-degraded products denoted with irr- prefix
(closed symbols, solid lines). Error bars not visible are smaller than the symbol size.
Panel A, n = 6 replicate experiments; panels B-C, n = 3 replicate experiments. *, p<0.05;
**, p<0.01; ***, p<0.001; ****, p<0.0001 as determined by one-way ANOVA for each
compound as compared to lowest concentration tested, 0.08 M.

(Figure 15A). Because cell viability was greater than 50% at all test concentrations of
Irr-Flav-1, an IC50 value was not determined.
Modification of the core Flav-1 structure by addition of the TPP tail moiety with
either two (C2) or eight carbons (C8) altered the apparent toxicity of this CORM as
determined by the MTT assay in A549 cells. Both Mito-Flav-C2 and -C8 were more
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toxic than the core structure, with mean IC50 values of 14.1±2.7 and 8.48±4.0 µM,
respectively, (Figure 15B-C; Table 2). At the highest concentration tested, cell viability
was reduced by about 85% for both compounds. Unlike Flav-1 (Hillslope of -2.2), the
slopes of the concentration-response curves for the TPP-modified structures were not as
steep (Hillslope values of -0.68 and -0.78, respectively), such that low micromolar
concentrations of Mito-Flav-C2 and -C8 also significantly reduced cell viability. Of note,
irradiation of Mito-Flav-C2 completely ameliorated its apparent cytotoxicity, as no
decrease in cell viability was evident (Figure 15B). However, irradiation of Mito-FlavC8 was not as effective, as this compound retained moderate toxicity with an estimated
IC50 value of 69.1±11 µM. Compared to its parent compound, Irr-Mito-Flav-C8 was
substantially less toxic, as concentrations ≤ 10 µM did not significantly reduce cell
viability (Figure 15C).
The base Flav-1 structure was less cytotoxic in HUVECs compared to the A549
cancer cell line, with a maximum decrease in cell viability of 35% at 100 µM and no
apparent decrease at lower concentrations (Figure 16A). However, the irradiated
compound was similarly not cytotoxic, with no apparent decrease in cell viability. As
was observed in A549 cells, the TPP-modified structures were considerably more
cytotoxic in HUVECs than the core structure, Flav-1 (Figure 16). However, the relative
toxicity of the mitochondria-targeted CORMs differed depending on the solvent, EtOH or
DMSO, used to deliver Mito-Flav-C2 and -C8 to cells. First, Mito-Flav-C2 delivered via
DMSO significantly decreased cell viability by up to 77% with a mean IC50 value of
1.51±1.4 µM (Figure 16B). On the other hand, viability of HUVECs treated with Mito-
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Figure 16. Toxicity of Flav-1, Mito-Flav-C2, Mito-Flav-C8, and their irradiated products
in HUVECs measured by the MTT assay. Values shown are the mean ± SEM percent
viability of cells with respect to the control (0.4% DMSO for panels A, B, and D; 0.2%
EtOH for panels C and E) for various concentrations of Flav-1 (A), Mito-Flav-C2 (B-C)
and Mito-Flav-C8 (D-E). Cell viability data and non-linear regression analyses (fourparameter, variable slope) are shown for the native compounds (open symbols, dashed
lines) and their irradiated products denoted with irr- prefix (closed symbols, solid lines).
Error bars not visible are smaller than the symbol size. Panel A, n = 12 replicate
experiments; panels B-E, n = 3 replicate experiments. *, p<0.05; **, p<0.01; ***,
p<0.001; ****, p<0.0001 as determined by one-way ANOVA for each compound as
compared to lowest concentration tested, 0.08 M.
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Flav-C2 in EtOH was substantially greater, with a maximum decrease of only 34%
observed at 100 µM (Figure 16C). As observed in A549 cells, irradiation of Mito-FlavC2 markedly reduced the toxicity of the compound, with no apparent decrease in cell
survival at concentrations ≤50 µM, irrespective of the solvent used (Figure 16B-C).
A different pattern was seen for Mito-Flav-C8, which decreased survival of
HUVECs by 51% and 54% when delivered via DMSO or EtOH, respectively. In
HUVECs, the average IC50 value of 8.40±3.6 µM for Mito-Flav-C8 in DMSO was very
similar to that observed for A549 cells, whereas Mito-Flav-C8 delivered via EtOH
resulted in a moderately higher IC50 value of 31.9±14 µM (Figure 16D-E). While
irradiation of Mito-Flav-C8 markedly decreased the average IC50 (90.0±7.5 and 108±14
µM in DMSO and EtOH, respectively), the high concentration of 100 µM was similarly
cytotoxic as the non-irradiated compound. However, Irr-Mito-Flav-C8 did not decrease
cell viability at concentrations below 10 µM, as reflected by the apparent differences in
the estimated Hillslopes for the regression curves (-0.28 or -0.34 for non-irradiated
compared to -1.099 or 1.367 for irradiated Mito-Flav-C8 in solvents DMSO or EtOH,
respectively).
Cytotoxicity determined by the LDH assay. A second cell viability assay was
used to evaluate the impact of Flav-1, Mito-Flav-C2 and Mito-Flav-C8 and their
irradiated products in HUVECs. As shown in Figure 17, results of this assay suggest that
Mito-Flav-C2 and -C8 were substantially less toxic as compared to results for similar
experiments using the MTT assay, with a maximal decrease in viability of only 24% and
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Figure 17. Toxicity of Flav-1, Mito-Flav-C2, Mito-Flav-C8, and their irradiated products
in HUVECs measured by the LDH assay. Values shown are the mean ± SEM percent
viability of cells with respect to the control (0.4% DMSO) for various concentrations of
Flav-1, Mito-Flav-C2 (A) and Mito-Flav-C8 (B). Cell viability data and non-linear
regression analyses (four-parameter, variable slope) are shown for the native compounds
(open symbols, dashed lines) and their irradiated products denoted with irr- prefix (closed
symbols, solid lines). (Irradiated Flav-1 not included in this assay). Error bars not visible
are smaller than the symbol size. For both panels, n = 5 replicate experiments for Flav-1
and n = 3 replicate experiments for other compounds. *, p<0.05; **, p<0.01; ***,
p<0.001; ****, p<0.0001 as determined by one-way ANOVA for each compound as
compared to lowest concentration tested, 0.08 M.

26%, respectively. However, none of the compounds tested reduced cell viability by
more than 50%, and no IC50 values could be determined.
Visualization of CORM uptake and cellular localization by confocal microscopy.
Using standard fluorescence microscopy, our group previously showed that incubation
with high concentrations of Flav-1 led to the accumulation of this CORM in the
cytoplasm of A549 cells (Anderson, et al., 2015). In this study, we employed confocal
microscopy to visualize uptake of Flav-1, Mito-Flav-C2, and Mito-Flav-C8 in both A549
and HUVEC cells. Initial experiments focused on identifying the appropriate conditions
for loading these CORMs into the target cells and visualization by the confocal
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Figure 18. Qualitative assessment fluorescence emission intensity of photoCORMs in
A549 cells and HUVECs. Signal intensity of Flav-1, Mito-Flav-C2, or Mito-Flav-C8
of A549 cells (A, B) or HUVECs (C). Cells in panels A and C were incubated for 4 h
with 100 M of each CORM, while cells in panel B were incubated for 4 h with 25 to
100 M of Mito-Flav-C2. The strength of signal was assessed qualitatively by two
individuals, and the numbers of cells imaged for each treatment is indicated in
parentheses.

microscope, including varying the compound concentration and the time of incubation.
Data presented in Figure 18 and summarized in Table A1 give an overall assessment of
the entire data collection for confocal microscopy imaging of these CORMs.
Fluorescence signal intensity was ranked using the following qualitative terms: strong,
moderately strong, moderate, moderately weak, weak, faint, and no signals. The initial
experiments assessed a 1 h or 4 h incubation period in complete culture media. Cells
were also treated with 25 µM to 100 µM Mito-Flav-C2 to determine if a concentration
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response could be visualized. An optimal fluorescence signal was obtained for cells
treated with 75 μM or 100 μM, while a loading time of 4 h was determined to be most
suitable for Mito-Flav-C2 and Mito-Flav-C8 for both cell lines. As indicated in Figure
18 and visualized in Figure 19E, no light emission for Flav-1 in A549 cells was

Figure 19. Confocal microscopy depicting cellular uptake of Flav-1, Mito-Flav-C2, and
Mito-Flav-C8 in A549 cells. Cells were treated with vehicle media control (0.4%
DMSO) (A-C), 100 µM Flav-1 (D-F), 100 µM Mito-Flav-C2 (G-I) or 100 µM Mito-FlavC8 (J-L) for 4 h. Representative images shown depict the Hoechst 33342 nuclear stain
(blue), the CORM (green) or a merge of the two fluorescence channels. Experiments
were repeated at least three times, and a minimum of 21 cells were visualized for each
experiment. Scale bar indicates 20 µm.
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Figure 20. Confocal microscopy depicting cellular uptake of Flav-1, Mito-Flav-C2, and
Mito-Flav-C8 in HUVECs. Cells were treated with vehicle media control (0.4% DMSO)
(A-C), 100 µM Flav-1 (D-F), Mito-Flav-C2 (G-I) or Mito-Flav-C8 (J-L) for 4 h.
Representative images shown depict the Hoechst 33342 nuclear stain (blue), the CORM
(green) or a merge of the two fluorescence channels. Experiments were repeated at least
three times, a minimum of 18 cells were visualized for each experiment. Scale bar
indicates 20 µm.

detectable by confocal microscopy, and only a faint emission was evident in HUVECs
(Figure 20E). However, strong emission intensity was clearly evident in both A549 cells
and HUVECs treated with Mito-Flav-C2 (Figures 19H, 20H), and light emission intensity
was positively correlated with the concentration of Mito-Flav-C2 in A549 cells (Figure
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18B). Alternatively, the emission intensity for Mito-Flav-C8 was moderately diminished
as compared to -C2, with only 47% of the A549 cells imaged having a strong or
moderately strong signal for the longer tailed compound compared to 77% of cells for the
short-tailed CORM (Figures 18A, 19K). In HUVECs, emission intensity for cells treated
with 100 M of the -C2 modified compound was qualitatively greater (43.5% of cells
with strong intensity) compared to those treated with the -C8 modified CORM (0% of
cells with strong intensity) (Figures 18C, 20K). Overall, these data suggest that, at the
same loading concentration, the emission signal for Mito-Flav-C2 was more robust in

Figure 21. Light induced photodegradation of Mito-Flav-C2. A549 cells were treated
with 25 µM Mito-Flav-C2 in 0.1% DMSO for 4 h, then counterstained with Hoechst
33342 prior to confocal microscopy. After obtaining initial images at wavelengths 410492 nm for the nuclear stain (blue) and 495-611 nm for the CORM (green) (A-B), the
cells were exposed to light at wavelength 488 nm (C) or 405 and 488 nm (D) for 5 min
and then re-imaged. Images are representative of 79 total cells visualized over one
experiment. Scale bar indicates 20 µm.
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both cell lines compared to Mito-Flav-C8, and both TPP-modified CORMs had
substantially greater detection than the core Flav-1 structure.
The next objective was to determine whether light exposure via the confocal
microscope would trigger CO release and loss of fluorescence emission at the measured
range (495-581 nm). Incubation of A549 cells with 25 µM Mito-Flav-C2 for 4 h led to a
moderately strong fluorescence signal (Figure 21) as compared to the prior experiment
using a 100 µM concentration (Figure 19). Following a 5 min exposure to light at
wavelength of 488 nm, nearly all Mito-Flav-C2 signal had disappeared (Figure 21C). A
complete loss of fluorescence signal was apparent when cells were exposed to light at
both 405 and 488 nm wavelengths for 5 min (Figure 21D). These results suggest that
light-induced CO release can be achieved in cell culture, in a similar manner as cell-free
based assays.
To assess co-localization, our experiments incorporated MitoTracker Red
CMXRos (MTR) as a fluorescent stain due to its known localization in the mitochondria,
which are mainly found in proximity to the nucleus (Buravkov et al., 2014). Mito-FlavC2 and Mito-Flav-C8 readily localized near the mitochondria of A549 cells treated with
100 µM of either CORM when incubated for 4 h, indicated by the yellow-orange color in
the merged image (Figure 22H, L). Note that the strong emission intensity for Mito-FlavC2 consistently masked the signal from MTR, yielding only bright yellow-green in the
merged image (Figure 22H). There was no apparent overlap in light emission for MTR at
the wavelengths for detection of CORM, assuring us that the signal detected for CORM
was genuine (Figure 22C).
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Figure 22. Co-localization of TPP-appended compounds with mitochondria in A549
cells. Cells were treated with vehicle control (0.4% DMSO) (A-D), 100 µM Mito-FlavC2 (E-H) or Mito-Flav-C8 (I-L) for 4 h, then counterstained with Hoechst 33342 and
MitoTracker Red CMXRos. Representative images shown depict the Hoechst nuclear
stain (blue), the MitoTracker mitochondria stain (red) the CORM (green) or a merge of
the three fluorescence channels. Experiments were repeated at least five times, and at
least 21 cells were visualized for each experiment. Scale bar indicates 20 µm.

Importantly, the morphology of mitochondrial in cells treated with TPP-modified
photoCORMs appeared to differ compared to cells incubated in plain media (Figure 22B,
F, J). The structure of mitochondria in untreated cells was filamentous, whereas
mitochondria in cells treated with Mito-Flav-C2 or -C8 tended to have a round shape.
However, these pronounced effects on mitochondrial morphology were not as apparent at
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25 µM Mito-Flav-C2 (Figure 21A and B). Additional experiments were performed at a
higher magnification to observe in greater detail the mitochondrial morphology of A549
cells treated with Mito-Flav-C2 compared to media control (Figure 23). Notably,
mitochondria of cells treated with 75 µM Mito-Flav-C2 appeared to swell and round up,
losing their filamentous structure. Also, it was noted that the localization of this TPP-
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Figure 23. High magnification images showing Mito-Flav-C2’s co-localization with and
impact on mitochondria structure in A549 cells. Cells were treated with vehicle control
(0.4% DMSO) (A-D) or 75 µM Mito-Flav-C2 (E-L) for 4 h, then counterstained with
Hoechst 33342 and MitoTracker Red CMXRos. Images shown were obtained at 63
magnification and then subjected to a 2 digital zoom to better visualize subcellular
structures. Image panels depict the Hoechst nuclear stain (blue), the MitoTracker
mitochondria stain (red) the CORM (green) or a merge of the three fluorescence
channels. Scale bar indicates 10 µm.

43

Figure 24. Co-localization of TPP-appended compounds with mitochondria in HUVEC
cells. Cells were treated with vehicle control (0.4% DMSO) (A-D), 100 µM Mito-FlavC2 (E-H) or Mito-Flav-C8 (I-L) for 4 h, then counterstained with Hoechst 33342 and
MitoTracker Red CMXRos. Representative images shown depict the Hoechst nuclear
stain (blue), the MitoTracker mitochondria stain (red) the CORM (green) or a merge of
the three fluorescence channels. Experiments were repeated at least three times, and at
least 18 cells were visualized for each experiment. Scale bar indicates 20 µm.

appended compound was closely aligned with MTR (Figure 23F, J), which was not as
easily discerned at the higher test concentration.
Similar results for CORM co-localization with mitochondria were observed in
HUVECs. Mito-Flav-C2 and Mito-Flav-C8 co-localized with the mitochondria as shown
by the yellow-orange color in the merged image (Figure 24H, L). However, the emission
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intensity in response to 100 M Mito-Flav-C2 in HUVECs was not as pronounced as for
A549 cells, and punctate localization throughout the cell was evident with partial overlap
with the MTR signal (Figure 24G, H). Morphology of mitochondria in untreated cells
remained filamentous, whereas mitochondria in CORM-treated cells were more spherical
in shape (Figure 24B, F, J). No distinct differences in mitochondria shape were noted
when comparing between the -C2 or -C8 CORM structures.

45
DISCUSSION
This study details the cytotoxicity and the localization of Flav-1 to the
mitochondria of HUVEC and A549 cells after being modified with a TPP moiety. As
such, these novel mitochondria-targeting photoCORMs represent the first CORMs with
the capacity to target a specific organelle, which may have important applications in the
study of the biological effects of CO. Furthermore, this work shows that the modified
Mito-Flav-C2 and -C8 structures retained several desirable properties of the Flav-1 core
structure, including light-triggered CO release, solubility in aqueous solution, and in vitro
trackability by fluorescence light emission. The use of previous CORM structures has
aided substantially in understanding the physiological importance of CO. However, these
new photoCORMs that facilitate CO release in proximity of mitochondria may shed new
light on the effects of this important gasotransmitter.
Several groups have recognized that certain features must be present in newer
CORMs to fully understand the mechanistic aspects of CO and, thus, advance the study
of the impact of CO on cellular physiology (Garcia-Gallego and Bernardes, 2014; Kautz,
et al., 2016; Mann, 2012; Motterlini and Foresti, 2017; Motterlini and Otterbein, 2010;
Schatzschneider, 2015). Notably, these features include controlled and localized release
of CO, a core structure amenable to chemical modification, and in vitro trackability, all of
which are properties attributable to Flav-1. For example, the tunable nature of the Flav-1
core structure was recently demonstrated via the development of a “sense-of-logic”
photoCORM, which is able to sense and react with free thiols, convert to Flav-1 and then
release CO after exposure to visible light and oxygen (Soboleva et al., 2017). Another
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example of the structural tunability of Flav-1 was also shown by the development of zinc
flavonolato complexes, which improved the photochemical properties of Flav-1 by
coordination with a zinc(II) ion (Anderson et al., 2016). The presence of the zinc ion
red-shifted the absorption spectrum (required lower energy light for CO release) and
increased the quantum yield (fewer photons absorbed per molecule of CO released).
Also, addition of zinc provided for CO release when the compound was in the solid state
and when solubilized, whereas the unmodified Flav-1 structure only released CO when in
solution (Anderson, et al., 2016). In the present study, by adding a TPP-tail moiety to
Flav-1, we improved upon two key limitations of most current CORMs: spatial location
and timing of release. In the field of gasotransmitters, only one other mitochondriatargeting molecule is currently available – a nitric oxide-releasing molecule that
incorporates a TPP tail in its structure and has a carbon-dot motif to facilitate tracking by
fluorescence emission (Xu et al., 2015).
Results from the MTT cytotoxicity assays showed that Flav-1 was moderately
toxic to A549 cells (similar to our prior observations (Anderson, et al., 2015)), but the
toxicity of this core structure was markedly decreased in HUVECs. Meanwhile, the
irradiated version of Flav-1 did not impair viability of either cell line even at the highest
tested concentration. The increased toxicity of Flav-1 in A549 cells could be explained
by the aberrant metabolism characteristic of cancer cells, which typically display
Warburg-like metabolism (high rates of glycolysis with cytosolic lactic acid
fermentation) (Potter et al., 2016). The addition of the TPP-tail to the core structure of
Flav-1 moderately increased cytotoxicity of this CORM in both cell lines. Mito-Flav-C8
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(in DMSO) had similar toxicity in both cell lines, while Mito-Flav-C2 (in DMSO)
appeared more toxic in HUVECs than in A549 cells by an order of magnitude. Limited
additional cytotoxicity assays were performed using EtOH as a vehicle for delivering the
TPP-appended CORMs. However, we observed that solubility of Mito-Flav-C2 and -C8
was inconsistent for stock solutions prepared in ethanol. Therefore, the cytotoxicity data
obtained for these CORMs delivered via ethanol to cells must be interpreted with caution.
Also, an initial confocal imaging pilot experiment revealed a much-reduced fluorescence
signal in cells treated with Mito-Flav-C8 prepared in ethanol compared to DMSO. Thus,
DMSO was used as the vehicle for delivery of the photoCORMS for all further cell
culture and confocal imaging experiments. As a polar aprotic solvent, DMSO was likely
a more suitable carrier for these photoCORMs, which are somewhat hydrophobic and
have limited capacity for forming hydrogen bonds. Moreover, DMSO is useful for
delivering these hydrophobic compounds to cells by facilitating the transitions between
the aqueous phase and the lipid membrane phase of the plasma membrane.
Other researchers employing the TPP motif have also assessed the impact of that
structural modification on chemical cytotoxicity, with results broadly similar to those
observed in this study. In their review, James and colleagues (2005) noted that MitoQ10,
a TPP-tail modified co-enzyme Q10 molecule, was toxic to yeast at concentrations 1
µM, but that concentrations below 1 µM were not acutely toxic in mammalian cells.
However, the effect of the length of the TPP-tail or the hydrophobicity of the TPPappended compound on cells was unknown. Ross et al. (2008) compared the uptake of
two hydrophobic TPP derivatives into mitochondria of intact cells, including MitoQ10
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(termed MitoQ in their manuscript) and decylTPP (contains a 10-carbon tail), to the more
hydrophilic TPP cation methyltriphenylphosphonium (TPMP) with a single carbon tail.
They observed that uptake of MitoQ10 and DecylTPP occurred more rapidly (minutes as
opposed to hours) and to a much greater extent than was observed for TPMP. In a later
study, Reily et al. (2013) examined the effects of several mitochondrially-targeted
antioxidants of varying TPP tail lengths on mitochondria bioenergetics in mouse
mesangial cells to corresponding TPP structures that lacked the antioxidant group. They
determined that the mitochondrial respiration rate was inversely correlated with alkyl
chain length (greater inhibition at longer chain lengths) and with greater hydrophobicity.
Similar results were observed by Trnka et al. (2015) using intact C2C12 myoblasts. In
addition, these researchers noted a decrease in mitochondrial respiratory chain complexes
when they treated rat skeletal muscle homogenates with 1 µM TPP with alkyl chains 10
or 12 carbons in length. Based on this observation, these authors expressed caution
regarding the design of TPP-appended molecules due to the biologically active
component of the TPP motif itself. Moreover, these moieties can adsorb to the matrix
surface of the inner mitochondrial membrane, which may mediate their toxicity (Murphy
and Smith, 2007). Thus, the addition of the TPP motif at high concentrations may cause
cellular toxicity because of the effect of the TPP structure on mitochondrial respiration
and integrity. Despite this apparent drawback, the TPP moiety may be useful for targeted
delivery of signaling molecules, such as CO, to the mitochondria, as highlighted by other
researchers (Graham, et al., 2009; Logan and Murphy, 2017; Mattarei et al., 2008;
Murphy and Smith, 2007; Smith, et al., 1999). Such may be the case for Mito-Flav-C2
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or -C8, especially if a modulating effect can be achieved at substantially lower
concentrations due to the proximity of CO release near its intracellular target organelles
and/or molecules.
Although Mito-Flav-C2 and Mito-Flav-C8, as of now, are the first CORMs that
can target mitochondria, other molecules have been synthesized with TPP-tails of varying
lengths to deliver active compounds to mitochondria. Many of these molecules are
already known for certain therapeutic properties. Notably, compounds modified to
decrease mitochondrial production of reactive oxygen species include MitoSOD,
MitoPeroxidase, MitoTEMPOL, MitoQ10, and MitoE2, which were designed to reduce
O2-, H2O2, Fe2+, and lipid peroxidation, respectively (Figure 8) (Murphy and Smith,
2007). For example, MitoE2 protected isolated rat mitochondria from oxidative damage
more effectively than vitamin E alone (Smith, et al., 1999). Similarly, Mattarei et al.
(2008) synthesized a TPP-appended quercetin analogue, which had cytostatic and
cytotoxic properties against murine colon cancer cells or fast-growing murine embryonic
fibroblasts. Thus, TPP-tailed motifs are efficient modifications that allow selective
accumulation to the mitochondria increasing their effectiveness against mitochondria
induced oxidative damage.
Most CORM structures are metal carbonyls, and first-generation CORMs
incorporated a manganese or ruthenium metal center (Figure 1). Later CORM structures
incorporated other metals, such as iron, molybdenum, iridium, rhenium, tungsten, cobalt,
or chromium, as well as boron as a metalloid (Kautz, et al., 2016). Although many of
these metals are present in the body as trace elements, the toxicity of the metal center
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post-CO release has not been clearly evaluated for all compounds. Indeed, in some cases,
the toxicity of the CO release reaction product(s) has not been assessed at all. For
example, CORM-3, a widely-used CORM, has low apparent cytotoxicity with no
observed significant effects on viability of porcine aortic endothelial cells or primate
peripheral blood mononuclear cells at concentrations less than 500 μM as determined by
the MTS assay (Vadori et al., 2009). Despite the low toxicity of CORM-3 in these cell
lines, therapeutic use may be difficult due to its complex solvent-dependent chemistry.
At a physiological pH, CORM-3 forms several isomers and adducts that may prove
difficult to track and may also have variable CO release kinetics (Schatzschneider, 2015).
A study performed by Nobre et al. (2016) characterized several metal containing CORMs
as generally non-toxic against murine macrophages (RAW 264.7), porcine kidney
epithelial (LLC-PK1), and human hepatoma (HepG2) cells. Nobre and colleagues noted
that concentrations greater than 50 µM of these metal-containing CORMs were required
to induce significant cell death, while in some cases, no cell death was observed even at
500 µM, as determined by the MTT assay. Also using the MTT assay, Gong et al. (2016)
showed that cobalt-based CORMs had IC50 values ranging from 36.2 to 125 µM in HeLa
(cervical cancer) cells and 39.3 to 139 µM in HepG2 cells. The toxicity of ironcontaining ET-CORMs was assessed by Romanski et al. (2013) in HUVEC and proximal
tubular epithelial cells (PTEC). They observed that only two of the tested compounds
were toxic at 100 µM, while most were only toxic at 1000 µM, also measured by the
MTT assay. On the other hand, only two other organic photoCORMs have been
reported: a diketone derivative, which requires micelle encapsulation for light-induced
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release (Peng, et al., 2013), and a xanthene-9-carboxylic acid compound that releases CO
when irradiated with 500 nm light (Antony, et al., 2013) (Figure 4). The diketone
derivative was shown to be non-toxic up to the highest tested concentration of 40 µM in
KG1 (leukemia) cells. However, the toxicity of the xanthene-9-carboxylic acid
compound was not determined. Considering these available reports, the apparent
cytotoxicity of Flav-1 in HUVECs is moderate as compared to other CORM structures.
Alternatively, the higher toxicity reported for Mito-Flav-C2 and -C8 remains consistent
with that of other TPP-appended compounds. Though this motif increases the apparent
toxicity of the CORM structure, the capacity for mitochondrial targeting imparts an
advantage that may overcome the limitation. It is conceivable that the tail may allow for
accumulation of the CORM proximal to the mitochondria, so that one could achieve
physiologically-relevant concentrations of CO near the metabolic systems with which it
may interact at CORM concentrations that are not toxic to the overall cells. Thus, one
may be able to achieve therapeutic effects of these biologically-based photoCORMs at
concentrations well below those that cause adverse effects in cells. That said, to retain
the utility of these CORMs for imaging at lower concentrations, the light emission
intensity yield per molecule would need to be improved.
In this study, cytotoxicity of all three photoCORMs was estimated to be much
lower using the LDH assay as compared to the MTT assay in HUVECs. A plausible
explanation for this outcome is that the MTT assay measures mitochondrial respiration
rate via conversion of tetrazolium salts into formazan dyes, while the LDH assay detects
the release of LDH into the extracellular environment, which is indicative of membrane
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damage. Thus, the MTT assay is a good indicator of dysfunctional mitochondrial
bioenergetics, which typically leads to apoptosis, while the LDH assay is useful for
assessing later stages of cell death, such as necrosis. Given the apparent difference in
estimated cytotoxicity of these photoCORMs, it is possible that they triggered apoptosis
in HUVECs during the 24 h period of incubation. Also, as discussed previously, the
structure of the TPP-appended compounds may alter mitochondrial respiration. If the
photoCORM induced a mild de-coupling of the electron transport chain leading to a
reduced cellular respiration rate, then cell viability likely would be underestimated using
the MTT assay. However, the impact of either Mito-Flav-C2 or Mito-Flav-C8 (prior to
or after CO release) on mitochondrial respiration has yet to be determined.
Confocal microscopy confirmed uptake and co-localization of Mito-Flav-C2 and
Mito-Flav-C8 to the mitochondria of HUVEC and A549 cells. Fluorescence intensity
was stronger in Mito-Flav-C2 treated cells when compared to those incubated with MitoFlav-C8, which may be indicative of greater cellular uptake by Mito-Flav-C2. Also,
uptake of both compounds appeared greater in A549 cells. We noted that short-term
incubation of cells with 100 µM Mito-Flav-C8 had a negative impact on cell
morphology, despite the apparent increase in fluorescence intensity observed by confocal
microscopy. In contrast, a short-term, 4 h incubation with Mito-Flav-C2 yielded a robust
fluorescence signal without apparent cellular damage, and, thus, -C2 was the focus of the
remaining imaging experiments. Also, the decreased accumulation of Mito-Flav-C8 in
mitochondria as compared to Mito-Flav-C2 may be explained by the longer alkyl chain
length, which decreases the mitochondrial membrane potential (Trnka, et al., 2015). An
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increase in membrane permeability of the mitochondria would lead to faster
depolarization, which would affect the targeting capabilities of TPP-motifs by disrupting
the electrical potential. Accumulation of TPP-appended compounds near mitochondria
has been shown to be hindered by treatment with carbonyl-cyanide-ptrifluoromethoxyphenylhydrazone (FCCP), which is an ionophore that disrupts the
electron transport chain (Ross, et al., 2008). Furthermore, Mattarei et al. (2008), showed
that treatment with 2 µM FCCP caused diffusion of TPP-appended quercetin analogues
into the cytosol of HCT116 (colorectal carcinoma) cells. In addition to uptake and colocalization, treatment with Mito-Flav-C2 and -C8 caused substantial changes to
mitochondrial morphology. High resolution confocal images of A549 cells treated with
75 µM Mito-Flav-C2 depicted enlarged, rounded mitochondria, indicative of high
cellular stress. In contrast, mitochondria of untreated cells were tubular or filamentous in
shape, indicative of metabolically active, normal-functioning mitochondria (Willems et
al., 2015). As explained previously, depolarization of the mitochondrial membrane (as
with FCCP treatment) impairs the accumulation of TPP-appended compounds at the
mitochondria. Increasing concentrations of these photoCORMs to facilitate visualization
via fluorescence microscopy introduced a secondary problem of altered mitochondria
morphology. Conversely, reducing the concentration of Mito-Flav-C2 and -C8 in cells
may allow for greater accumulation at the mitochondria without triggering
depolarization. However, low concentrations of these compounds might not be
detectable by confocal microscopy due to exposure to laser light when acquiring an
image or by low fluorescence intensity. Therefore, a balance between detection and
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accumulation must be met. In practice, researchers using Mito-Flav-C2 or -C8 may load
cells at high concentrations to optimize loading time and confirm cellular uptake, and
then employ lower concentrations in cellular studies aimed to elucidate the biological
effects of CO, such as studies of mitochondrial bioenergetics.
Interestingly, photo-degradation of Mito-Flav-C2 could be performed using 405
or 488 nm lasers, which modulated the time required to completely photodegrade the
CORM. Also, photodegradation occurred when utilizing a bright-field source, which
excited at a broad spectrum of visible light (data not shown). CO release from MitoFlav-C2 was achieved very rapidly when exposed to both 405 and 488 nm lasers, was
moderately slower when exposed to only 488 nm light, and was slowest when exposed to
a bright-field source. Thus, CO release can be triggered without the use of near UV-light,
unlike most photoCORMs (Wright and Wright, 2016). An ideal photoCORM will
release CO when exposed to wavelengths above 600 nm (red and infrared regions) to
maximize tissue penetration and avoid the damaging effects of high energy light.
Motterlini and Foresti (2017) noted the importance of CO release in the proximity
of physiological targets. In their recent review, they observed that location of CO release
(intra- or extracellularly) dictates the concentration required to produce physiological
effects. Inhaled CO is the least effective method for CO delivery because exposure
concentrations must be sufficiently high to overcome binding to circulating hemoglobin
and myoglobin in order to reach peripheral tissues. Interestingly, CO released via
CORMs is detectable by a CO sensor, namely COP-1, but a detectable concentration of
CO is not triggered when heme oxygenase is induced by heme to produce endogenous
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CO (unpublished observation reported by Motterlini and Foresti, 2017). However, the
detection limit of COP-1 is about 1 µM, which may explain the inability of the probe to
detect endogenously generated CO (Michel et al., 2012). Recently, Liu et al. (2017)
developed a near-infrared fluorescent probe (1-Ac) capable of detecting endogenouslyproduced CO. Their experiments showed that Raw 264.7 cells and zebrafish embryos
cultured under hypoxic conditions produced a significantly higher fluorescent signal
compared to normoxic culture conditions. In addition, the group further demonstrated the
utility of their CO sensor by using 1-Ac to detect endogenous production of CO
stimulated by induction of HO-1 with lipopolysaccharide and hemin in Balb/c mice
(2017). In the future, this new molecular tool for sensing CO release in vitro and in vivo
could be coupled with our new mitochondria-targeting photoCORMs for detailed
molecular investigations on CO impacts on mitochondrial bioenergetics, reactive oxygen
species generation, and subsequent cell signaling responses in the context of various
disease states, such as cardiovascular disease or cancer.
In conclusion, this study, in collaboration with Berreau and colleagues,
characterized and functionalized the first mitochondria-targeting CORM by adding a TPP
motif to Flav-1. Furthermore, modification of Flav-1 with TPP motifs did not alter its
desirable characteristics of visible light-induced CO release in the presence of oxygen,
fluorescence emission, solubility at non-toxic concentrations of DMSO, and a clean
reaction with no unknown by-products. Cytotoxicity of Mito-Flav-C2 and -C8, as
determined by the MTT assay, in HUVEC and A549 cells was significantly increased by
addition of the TPP tail compared to the base Flav-1 structure. However, this toxicity did
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not differ substantially from other existing TPP-appended molecules, and this increase in
toxicity may be due to an increase in uptake efficiency. Thus, increased cellular uptake
could allow cells to be treated with lower concentrations of Mito-Flav-C2 or -C8 to
achieve biological effects. Notably, confocal microscopy data showed that addition of
the TPP tail to the Flav-1 core structure facilitated greater uptake and localization to the
mitochondria of HUVEC and A549 cells, as expected. Interestingly, our data also
demonstrated that Mito-Flav-C2 was subject to photodegradation using varying
wavelengths of light and also a bright-field source, which may be used to trigger the
release of CO.
As research with these photoCORMs continues, new areas of focus are clear.
First, the most important next step is to assess the impact of Mito-Flav-C2 and -C8 and
light-triggered CO release from these compounds on mitochondrial bioenergetics.
Additionally, future work may include the use of 1-Ac or other CO reporters to assess the
release of CO within cells because low concentrations of Mito-Flav-C2 and -C8 would
not be detectable by their own fluorescence. Future cellular bioassays should also
provide for comparisons between mitochondria-targeted photoCORMs and other CORMs
that operate via ligand exchange or enzymatic trigger with respect to CO delivery and
changes in cell physiology (e.g., production of reactive oxygen species and activation of
oxidative stress response pathways). Lastly, this study exemplifies the successful
structural modification of the core structure of a CORM to achieve additional utility as a
molecular tool. Further modifications to the core structure may impart other desirable
characteristics, such as addition of motifs for other organelle targeting, or other structural
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modifications that improve the intensity of fluorescence emission, allow for CO release at
lower energy wavelengths or that increase the yield of CO release per molecule of
CORM.
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Figure A1. 1H NMR of Mito-Flav-C2 in DMSO-d6. Data shown with permission of
collaborators Tatiana Soboleva and Lisa Berreau, Utah State University.
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Figure A2. Absorption spectrum of Mito-Flav-C2 in CH3CN:DMSO (10:1). Data shown
with permission of collaborators Tatiana Soboleva and Lisa Berreau, Utah State
University.
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Figure A3. Overlay of normalized lowest energy absorption features of Mito-Flav-C2
with the emission spectrum in CH3CN:DMSO (10:1). Emission features at ~480 nm and
~603 nm represent normal (N*) and tautomeric (T*) excited forms of the flavonol core
respectively. Data shown with permission of collaborators Tatiana Soboleva and Lisa
Berreau, Utah State University.
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Figure A4. Absorption spectrum of Mito-Flav-C2 in DMEM F12 cell culture media with
and without 10% (v/v) FBS. Data shown with permission of collaborators Tatiana
Soboleva and Lisa Berreau, Utah State University.
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Figure A5. 1H NMR of Mito-Flav-C8 in DMSO-d6. Data shown with permission of
collaborators Tatiana Soboleva and Lisa Berreau, Utah State University.
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Figure A6. Absorption spectrum of Mito-Flav-C8 in CH3CN:DMSO (10:1). Data shown
with permission of collaborators Tatiana Soboleva and Lisa Berreau, Utah State
University.

77

Figure A7. Overlay of normalized lowest energy absorption feature of Mito-Flav-C8
with its emission spectrum in CH3CN:DMSO (10:1). Emission features at ~480 nm and
~603 nm represent normal (N*) and tautomeric (T*) excited states of the flavonol core
respectively. Data shown with permission of collaborators Tatiana Soboleva and Lisa
Berreau, Utah State University.
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Figure A8. Absorption spectrum of Mito-Flav-C8 in DMEM F12 cell culture media with
and without 10% (v/v) FBS. Data shown with permission of collaborators Tatiana
Soboleva and Lisa Berreau, Utah State University.
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Figure A9. 1H NMR of Irr-Mito-Flav-C2 in DMSO-d6 illuminated at 419 nm for 24 h.
Data shown with permission of collaborators Tatiana Soboleva and Lisa Berreau, Utah
State University.
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Figure A10. 1H NMR of Irr-Mito-Flav-C8 in DMSO-d6 illuminated at 419 nm for 24 h.
Data shown with permission of collaborators Tatiana Soboleva and Lisa Berreau, Utah
State University.
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Table A1. Summary of Confocal Microscopy Experiments with Flav-1, Mito-Flav-C2 and Mito-Flav-C8 in A549
and HUVEC Cell Lines.

81

C2
C8
C8

C8
C8 (EtOH)

HUVEC

HUVEC

HUVEC

HUVEC
HUVEC

100
100

100

100

100

Conc. (M)

4
4

4

4

4

Time (h)

7
5

8

12

8

Fields
of view

51
18

46

31

43

Cells
imaged

100
89

100

100

100

Positive
cells (%)

0
0

0

0

70

S

0
0

67

19

12

MS

69
44

17

58

19

M

25
44

0

19

0

MW

6
0

15

3

0

W

F

0
0

0

0

0

0

0

0

0
11

N

The intensity of the fluorescence signal was scored qualitatively as follows: S, strong; MS, moderately strong; M,
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Table A1. Summary of Confocal Microscopy Experiments with Flav-1, Mito-Flav-C2 and Mito-Flav-C8 in A549
and HUVEC Cell Lines.
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University." Please indicate your approval ofthis request by signing below in the space
provided, attaching any other form or instruction necessary to confirm permission. Thank you
for your assistance and collaboration.
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Hector Esquer
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emission spectrum in CH3 CN:DMSO
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without 10% (v/v) FBS
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Figure A9. NMR spectrum oflrr-Mito-Flav-C2
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